



TIME WAITS FOR NO ONE

Enlist the experts at Bio X Cell for  
Antibody Production Services

EXPLORE

RECEIVE 10% OFF NOW with code: CONTRACT22JI



## Cutting Edge: The Foxp3 Target miR-155 Contributes to the Development of Regulatory T Cells

This information is current as  
of March 2, 2022.

Susan Kohlhaas, Oliver A. Garden, Cheryl Scudamore,  
Martin Turner, Klaus Okkenhaug and Elena Vigorito

*J Immunol* 2009; 182:2578-2582; ;

doi: 10.4049/jimmunol.0803162

<http://www.jimmunol.org/content/182/5/2578>

**References** This article **cites 20 articles**, 11 of which you can access for free at:  
<http://www.jimmunol.org/content/182/5/2578.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days\*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*\*average*

**Subscription** Information about subscribing to *The Journal of Immunology* is online at:  
<http://jimmunol.org/subscription>

**Permissions** Submit copyright permission requests at:  
<http://www.aai.org/About/Publications/JI/copyright.html>

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://jimmunol.org/alerts>



## Cutting Edge: The Foxp3 Target miR-155 Contributes to the Development of Regulatory T Cells<sup>1</sup>

Susan Kohlhaas,<sup>2\*</sup> Oliver A. Garden,<sup>2†‡</sup> Cheryl Scudamore,<sup>§</sup> Martin Turner,<sup>\*</sup> Klaus Okkenhaug,<sup>\*</sup> and Elena Vigorito<sup>3\*</sup>

**Foxp3 is a transcription factor that is essential for the normal development of regulatory T cells (Tregs). In the absence of microRNAs (miRNAs), Foxp3<sup>+</sup> Tregs develop but fail to maintain immune homeostasis, leading to a scurfy-like disease. Global analysis of the network of genes regulated by Foxp3 has identified the miRNA miR-155, which is highly expressed in Tregs, as a direct target of Foxp3. In this study we report that miR-155-deficient mice have reduced numbers of Tregs, both in the thymus and periphery, due to impaired development. However, we found no evidence for defective suppressor activity of miR-155-deficient Tregs, either in vitro or in vivo. Our results indicate that miR-155 contributes to Treg development, but that additional miRNAs control Treg function. *The Journal of Immunology*, 2009, 182: 2578–2582.**

**R**egulatory T cells (Tregs)<sup>4</sup> constitute a subset of CD4<sup>+</sup> T cells essential for the maintenance of self-tolerance. The transcription factor Foxp3 is specifically expressed in Tregs and is a key regulator of their differentiation and suppressor function. Deficiency in Foxp3 results in severe autoimmune disease in both mice and humans (1). Expression of Foxp3 is needed to establish and maintain a particular transcriptional profile of protein-coding genes and microRNAs (miRNAs) that distinguishes Tregs from other T cell lineages (2–4).

miRNAs are 21- to 23-nt RNA molecules that regulate the expression of protein-coding genes. More than 700 miRNAs have been identified in mammals and have been implicated in a wide range of biological functions (5, 6). The biogenesis of miRNAs involves two processing steps, respectively catalyzed by the RNases Drosha and Dicer (reviewed by Bartel in Ref. 5).

Conditional ablation of Dicer has uncovered key roles for miRNAs in the development of B and T cells (7–9). More recently, conditional deletion of Drosha or Dicer in Foxp3<sup>+</sup> regulatory T cell lineages has implicated miRNAs as being essential for Treg function, because these mice develop a similar wasting disease to that observed in Foxp3-knockout mice (10–12). However, the specific miRNAs that are important for Treg function remain unidentified. miR-155 is an attractive candidate because Foxp3 binds to the promoter region of its host gene *bic*, and miR-155 is highly expressed in Tregs (2, 4, 13). Moreover, miR-155 is an important regulator of lymphocyte function and homeostasis (14, 15). However, the functional significance of miR-155 expression in Tregs has not been reported to date.

In this report, we investigated the contribution of miR-155 to Treg development and function. Mice deficient in *bic*/miR-155 showed reduced numbers of Tregs in the thymus and spleen. We found that Treg development required *bic*/miR-155, but that it was dispensable for Treg proliferation or survival in the periphery. Despite the lower number of Tregs, their suppressor function in vitro remained intact. Furthermore, no signs of spontaneous inflammatory bowel disease (IBD) were observed in young or aged miR-155-deficient mice, and miR-155-deficient CD4<sup>+</sup>CD25<sup>+</sup> T cells were able to prevent colitis induced by the adoptive transfer of CD4<sup>+</sup>CD45RB<sup>high</sup> T cells into lymphopenic hosts. Thus, miR-155 is required for development of the Treg lineage, but its absence does not overtly compromise Treg function in vitro or in vivo.

## Materials and Methods

### Mice

*bic*/miR-155-deficient mice, *bic*<sup>m2/m2</sup> (15), were backcrossed five times to the C57BL/6 background. Rag2<sup>-/-</sup> mice (16) on the C57BL/6 background were provided by F. Colucci (Babraham Institute, Cambridge, U.K.). All experiments were performed according to U.K. Home Office regulations.

\*Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, United Kingdom; †Regulatory T Cell Laboratory, Infection and Immunity Research Group, Department of Veterinary Clinical Sciences, Royal Veterinary College, Camden Campus, London, United Kingdom; ‡Department of Immunology, Imperial College London, Hammersmith Campus, London, United Kingdom; and §Department of Pathology and Infectious Diseases, Royal Veterinary College, North Mymms, Hatfield, Hertfordshire, United Kingdom

Received for publication September 23, 2008. Accepted for publication December 31, 2008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported by a Babraham Institute Synergy Grant. E.V. was supported by an Medical Research Council Career Development Award. Work in the laboratories of


K.O. and O.A.G. was funded by Biotechnology and Biological Science Research Council Project Grants.

<sup>2</sup> S.K. and O.A.G. contributed equally to this work.

<sup>3</sup> Address correspondence and reprint requests to Dr. Elena Vigorito, Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, CB22 3AT, U.K. E-mail address: elena.vigorito@bbsrc.ac.uk

<sup>4</sup> Abbreviations used in this paper: Treg, T regulatory cell; IBD, inflammatory bowel disease; miRNA, microRNA.

Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/\$2.00



**FIGURE 1.** Reduced number of Tregs in the absence of bic/miR-155. *A*, The percentage of CD4<sup>+</sup>Fopx3<sup>+</sup> cells in the thymus (Thy; *top panels*), spleen (Spl; *middle panels*), and inguinal lymph nodes (LN; *bottom panels*). Density plots are gated on CD4 single positive cells. In spleen and lymph node, most Fopx3<sup>+</sup> cells were also CD25<sup>+</sup>. *B*, The percentage of Fopx3<sup>+</sup> cells that are also CD4<sup>+</sup> cells in thymus (Thy), spleen (Spl), and lymph nodes (LN) (*left panel*) or the absolute number of Fopx3<sup>+</sup> cells in the same tissues (*right panel*) in wild-type mice (wt; open circles) and bic/miR-155-deficient mice (bic<sup>-/-</sup>; filled squares) is shown. Statistical differences between the two populations were determined by two-tailed student's *t* test. \*\*\*, *p* < 0.001; \*\*, *p* < 0.01; and \*, *p* < 0.05. *C*, Frequency of CD103<sup>+</sup>Fopx3<sup>+</sup> among CD4<sup>+</sup> cells in spleen (Spl) and lymph node (LN) of wild-type (wt) or bic/miR-155-deficient mice (bic<sup>-/-</sup>). Numbers indicate the percentage of cells in the designated gate as the mean and SD for three mice.

### Flow cytometry

Cells were stained for surface markers (antibodies from BD Biosciences or eBioscience) followed by Fopx3, according to instructions from eBioscience. Data were acquired with a FACSCalibur or LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo (Tree Star).

### Fopx3 induction

Naive CD4<sup>+</sup> T cells purified by negative selection (Miltenyi Biotec) were stimulated by plate-bound anti-CD3 and anti-CD28 mAbs in the presence of 1 ng/ml human TGF- $\beta$  (Peprotech). After 4 days, cells were stained for CD4 and Fopx3.

### Radiation chimeras

Bone marrow cells from wild-type or bic/miR-155-deficient mice were mixed at a 1:1 ratio and  $3 \times 10^6$  cells were injected into sublethally irradiated (500 rad) Rag2<sup>-/-</sup> mice. Chimeric mice were analyzed 7 wk after reconstitution.

### BrdU incorporation

Mice were injected daily with 0.8 mg of BrdU for 3 days. On day 4, spleen and lymph node cells were analyzed for BrdU incorporation by flow cytometry.

### CD4<sup>+</sup>CD25<sup>-</sup> suppression assay in vitro

CD25<sup>+</sup> and CD25<sup>-</sup> CD4<sup>+</sup> T cells were purified by positive and negative selection, respectively (Miltenyi); the purity of each population was >90% as determined by flow cytometry. A total of  $5 \times 10^4$  CD4<sup>+</sup>CD25<sup>-</sup> T cells were cultured with the indicated ratios of either wild-type or bic/miR-155-deficient CD4<sup>+</sup>CD25<sup>+</sup> T cells with 1  $\mu$ g/ml anti-CD3 and irradiated APCs for 72 h. The incorporation of [<sup>3</sup>H]TdR was measured over the last 6 h.

### CD4<sup>+</sup>CD25<sup>-</sup> suppression assay in vivo

CD4<sup>+</sup>CD25<sup>+</sup> and CD4<sup>+</sup>CD45RB<sup>high</sup> cells were isolated by cell sorting on a FACSaria flow cytometer, yielding populations of >99% purity. A published adoptive transfer model of colitis was used, injecting  $5 \times 10^5$  CD45RB<sup>high</sup> T cells alone or together with  $1 \times 10^5$  wild-type or bic/miR-155-deficient CD4<sup>+</sup>CD25<sup>+</sup> cells into Rag2<sup>-/-</sup> recipients (17). The severity of colitis up to 12 wk after injection was independently scored by O.A.G. and C.S., according to previously published criteria (18), and consensus scores are presented.


## Results and Discussion

### Reduced number of Tregs in the absence of bic/miR-155

Tregs were identified as CD4 single positive and Fopx3<sup>+</sup> in the thymus, spleen, and lymph nodes of adult mice. We found a 2- to 3-fold reduction in the frequency and absolute number of Tregs in the thymus and spleens from miR-155<sup>-/-</sup> mice (Fig. 1, *A* and *B*). A similar trend was observed in lymph nodes, though the results were more variable (Fig. 1, *A* and *B*). Similar results were observed in 3-wk-old mice (data not shown). In 1-year-old mice the phenotype was milder, as the number of Tregs was only marginally reduced in the thymus and spleen (data not shown). Despite a reduced number of Tregs, phenotypic analysis revealed normal expression of surface markers such as CD25, CTLA-4, GITR, or CD44 by Tregs from bic/miR-155<sup>-/-</sup> mice (Fig. 1*A* and data not shown). However, we observed a decrease in the proportion of miR-155-deficient Tregs expressing the  $\alpha_E\beta_7$  integrin CD103 (Fig. 1*C*).

The lower proportions and numbers of Tregs in the absence of miR-155 prompted us to investigate the requirement of miR-155 for development, proliferation, or survival of Tregs. To address the requirement of miR-155 for Treg development, we generated bone marrow chimeric mice by reconstituting sublethally irradiated Rag2<sup>-/-</sup> mice with a 1:1 mixture of wild-type (B6SJL) CD45.1 bone marrow cells with either wild-type (B6) or bic/miR-155 (bic)-deficient bone marrow cells expressing the allotypic marker CD45.2. Analysis after 7 wk showed that bone marrow precursors from wild-type CD45.2 cells were able to competitively reconstitute all lymphoid subsets. As expected, the ratio of CD45.2 to CD45.1 was ~1:1 (Fig. 2*A*;





**FIGURE 2.** miR-155 is required for the development of Tregs in an intrinsic manner. *A* and *B*, Representative example of flow cytometric analysis of thymocytes (*A*) and spleen (*B*) from 1:1 mixed chimeras 7 wk after bone marrow reconstitution. B6:B6SJL corresponds to the 1:1 mixture of wild-type CD45.2 and wild-type CD45.1 cells ( $n = 5$ ). bic<sup>-/-</sup>:B6SJL corresponds to the mixture of bic/miR-155-deficient precursors (CD45.2) with wild-type (CD45.1) cells ( $n = 4$ ). Density plots are gated on live lymphocytes based on forward and side scatter (left panels). Middle panels show CD4 vs CD8 profiles gated on CD45.1<sup>+</sup> (top) and CD45.2<sup>+</sup> (bottom) cells. Right panels show CD4 vs Foxp3 stain gated on CD45.1<sup>+</sup>CD4<sup>+</sup> (top) or CD45.2<sup>+</sup>CD4<sup>+</sup> (bottom) cells. In the CD4 vs Foxp3 density plots, the numbers indicate the percentage of cells in the designated gate as the mean and SD for five chimeric mice. *C*, Normal proliferation of bic/miR-155-deficient Tregs. The graph shows the proportion of BrdU<sup>+</sup> Tregs from spleen (SPL) and lymph nodes (LN) for three mice per group. In this experiment, Tregs were identified as CD4<sup>+</sup>CD25<sup>+</sup> owing to incompatibility of the Foxp3 and BrdU staining procedures. wt, Wild type.

CD45.1 vs CD45.2 stain and data not shown). Analysis of the wild-type CD45.1 and bic/miR-155<sup>-/-</sup> CD45.2 chimeras revealed a decreased proportion of bic/miR-155-deficient thymocytes and splenocytes (Fig. 2, *A* and *B*; CD45.1 vs CD45.2 stain). The decreased representation of miR-155<sup>-/-</sup> thymocytes was likely to be referable to a defect occurring at an early stage of development, as double-negative, double-positive, and CD4 and CD8 single-positive cells were all similarly under-represented (data not shown). In addition, the proportions of bic/miR-155-deficient double-negative, double-positive, CD4 or CD8 single-positive thymocytes were normal, arguing against a block at a later stage of development (Fig. 2*A*; CD4 vs CD8 stain). However, we found a relative reduction in the proportion of Foxp3<sup>+</sup> cells within the bic/miR-155<sup>-/-</sup> CD4<sup>+</sup> T cell subset (Fig. 2*A*; CD4 vs Foxp3 stain for bic:B6SJL chimeras) that indicated an intrinsic developmental defect. Similarly, the CD4 compartment in the spleen showed a reduced proportion of bic/miR-155-deficient Tregs compared with their wild-type counterparts (Fig. 2*B*; CD4 vs Foxp3 stain). Taken together, our results showed that bic/miR-155 is required for optimal Treg development in a T cell-intrinsic manner.

To test whether bic/miR-155 is required for Treg proliferation in the periphery, we measured the ability of CD4<sup>+</sup>CD25<sup>+</sup> T cells from spleen or lymph node to incorporate BrdU after continuous labeling for 3 days. The bic/miR-155<sup>-/-</sup> Tregs showed similar levels of BrdU incorporation, suggesting that miR-155 is not required for mature Treg cell cycling or survival *in vivo*.


To determine whether bic/miR-155 is required for Treg homeostatic proliferation and survival, we adoptively transferred

either wild-type or bic/miR-155-deficient Tregs (CD45.2) in combination with wild-type CD45RB<sup>high</sup>CD4<sup>+</sup> T cells (CD45.1) into lymphopenic mice and, after 5 wk, counted Tregs in both the spleen and mesenteric lymph nodes. We recovered similar numbers of wild-type or bic/miR-155-deficient Tregs from spleen and lymph nodes, indicating that bic/miR-155 is dispensable for homeostatic proliferation or survival of Tregs (data not shown).

In summary, our results support a requirement for miR-155 during thymic development of Tregs, but not for their maintenance or proliferation in the periphery.

#### *bic/miR-155 deficiency does not affect Foxp3 up-regulation or Treg-suppressive activity in vitro*


Peripheral T cells can be induced to express Foxp3 upon TCR stimulation in the presence of TGF- $\beta$ , providing a model for post-thymic Treg differentiation. As miR-155 is induced upon TCR activation, we wished to test whether it is required for Foxp3 induction. However, no impairment was observed in the ability of bic/miR-155-deficient T cells to up-regulate Foxp3 (Fig. 3*A*). We next assessed the ability of CD4<sup>+</sup>CD25<sup>+</sup> bic/miR-155-deficient cells to suppress the proliferation of wild-type CD4<sup>+</sup>CD25<sup>-</sup> cells stimulated by anti-CD3 in the presence of wild-type APCs. The bic/miR-155-deficient Tregs suppressed as effectively as wild-type cells in this assay (Fig. 3*B*). Similar results were observed when wild-type CD4<sup>+</sup>CD25<sup>-</sup> cells were stimulated by anti-CD3- and anti-CD28-coated beads (data not shown).



**FIGURE 3.** Normal Foxp3 induction and suppressor function of *bic*/miR-155-deficient Tregs in vitro. *A*, Foxp3 induction in vitro of wild-type (wt) or *bic*/miR-155-deficient (*bic*<sup>-/-</sup>) T cells. Unfilled lines indicate the isotype control and gray-filled lines indicate the Foxp3-stained cells. The mean and SD for three independent cultures was 78.5% ± 8.5% for wild-type cells and 81.4% ± 0.4% for *bic*/miR-155-deficient cells. *B*, Wild-type (wt) CD4<sup>+</sup>CD25<sup>-</sup> conventional T cells (Tconv) were stimulated with anti-CD3 in the presence of irradiated APCs at the indicated ratio of either *bic*/miR-155-deficient (*bic*<sup>-/-</sup>; closed squares) CD4<sup>+</sup>CD25<sup>+</sup> T cells (Tregs) or their wild-type counterparts (open circles). Data points represent the mean ± SEM of triplicate measures. One representative experiment of three is shown.

#### *bic*/miR-155-deficient Tregs show competent suppressor activity in vivo

We previously reported that *bic*/miR-155-deficient mice, *bic*<sup>m1/m1</sup>, displayed airway remodeling and developed enteric inflammation on a mixed 129/C57BL6 background (15). As impaired Treg function can lead to spontaneous IBD, we examined mice of 6 and 12 mo of age for signs of gastrointestinal inflammation. We noticed that up to 12–13 wk of age, the weight of wild-type and *bic*/miR-155-deficient mice was similar. Although older *bic*/miR-155-deficient mice were underweight (data not shown), histological analysis revealed no evidence of significant gastrointestinal inflammation. The lack of pathological lesions in *bic*/miR-155-deficient mice suggested that Treg suppressor capacity was not significantly impaired. However, as *bic*/miR-155 regulates the function of T cells and myeloid cells (14, 15, 19), concurrent defective T cell effector function might have protected the mice from spontaneous IBD. Moreover, although we found that *bic*/miR155<sup>-/-</sup> Tregs efficiently suppressed wild-type T cell proliferation in vitro, the mechanisms for in vivo suppression may be different. To assess the intrinsic suppressive function of *bic*/miR-155-deficient Tregs in vivo, we evaluated their ability to prevent colitis when cotransferred with wild-type CD4<sup>+</sup>CD45RB<sup>high</sup> T cells into immune-deficient recipients (17). In common with the wild-type Tregs, *bic*/miR155<sup>-/-</sup>CD4<sup>+</sup>CD25<sup>+</sup> T cells protected the Rag2<sup>-/-</sup> recipients from the colitogenic effect of cotransferred CD4<sup>+</sup>CD45RB<sup>high</sup> T cells (Fig. 4). Taken together, our results suggest that *bic*/miR-155 regulates the development of



**FIGURE 4.** *bic*/miR-155 is dispensable for Treg function in vivo. *A*, Rag2<sup>-/-</sup> mice were respectively injected with PBS (filled triangles), CD4<sup>+</sup>CD45RB<sup>high</sup> T cells (open triangles), or CD4<sup>+</sup>CD45RB<sup>high</sup> cells with wild-type (wt; open circles) or *bic*<sup>-/-</sup> Tregs (closed squares). Large intestine was collected 12 wk after injection and colonic inflammation was scored from 0 (normal) to 5 (severe colitis) using previously published criteria (18). *B*, Representative photomicrographs showing absence of inflammation in mice injected with PBS (*I*) but severe inflammation in mice injected with CD45RB<sup>high</sup> T cells (*II*) characterized by heavy infiltrates of predominantly mononuclear cells in the mucosa and submucosa, scattered neutrophils with microabscessation, crypt hyperplasia, and epithelial metaplasia and occasional ulceration. When either wild-type (*III*) or *bic*/miR-155-deficient (*IV*) Tregs were cotransferred with the CD45RB<sup>high</sup> T cells, colitis was not observed in the majority of mice. H&E staining was used; scale bar represents ~250 μm (original magnification: ×200).

Foxp3<sup>+</sup> cells, but not their suppressor function. As miR-155 has been reported as a Foxp3 target, miR-155 may contribute to the stability of the transcriptional program induced by Foxp3 by repressing unwanted genes. In addition, the reduced expression of CD103 on *bic*/miR-155<sup>-/-</sup> Tregs may affect their recruitment to sites of infection (20). Additional experiments are required to identify the molecular targets of miR-155 in developing Tregs. As miRNAs play a key role in the control of Treg homeostasis and function (10–12), other miRNAs, alone or in combination with miR-155, are likely to prove important for Treg biology.

## Acknowledgments

We thank Dan Patton, Nerys Evans, and Geoff Morgan for expert technical advice and assistance, Christine Lambart for animal husbandry, and Prof. Kenneth Smith for fostering the collaboration between O.A.G. and C.S.

## Disclosures

The authors have no financial conflict of interest.

## References

- Kim, J. M., J. P. Rasmussen, and A. Y. Rudensky. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat. Immunol.* 8: 191–197.
- Cobb, B. S., A. Hertweck, J. Smith, E. O'Connor, D. Graf, T. Cook, S. T. Smale, S. Sakaguchi, F. J. Livesey, A. G. Fisher, and M. Merkenschlager. 2006. A role for Dicer in immune regulation. *J. Exp. Med.* 203: 2519–2527.
- Gavin, M. A., J. P. Rasmussen, J. D. Fontenot, V. Vasta, V. C. Manganiello, J. A. Beavo, and A. Y. Rudensky. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. *Nature* 445: 771–775.
- Marson, A., K. Kretschmer, G. M. Frampton, E. S. Jacobsen, J. K. Polansky, K. D. MacIsaac, S. S. Levine, E. Fraenkel, H. von Boehmer, and R. A. Young. 2007. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. *Nature* 445: 931–935.
- Bartel, D. P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116: 281–297.
- Griffiths-Jones, S., R. J. Grocock, S. van Dongen, A. Bateman, and A. J. Enright. 2006. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res.* 34: D140–D144.
- Cobb, B. S., T. B. Nesterova, E. Thompson, A. Hertweck, E. O'Connor, J. Godwin, C. B. Wilson, N. Brockdorff, A. G. Fisher, S. T. Smale, and M. Merkenschlager. 2005. T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. *J. Exp. Med.* 201: 1367–1373.
- Koralov, S. B., S. A. Muljo, G. R. Galler, A. Krek, T. Chakraborty, C. Kanellopoulou, K. Jensen, B. S. Cobb, M. Merkenschlager, N. Rajewsky, and K. Rajewsky. 2008. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. *Cell* 132: 860–874.
- Muljo, S. A., K. M. Ansel, C. Kanellopoulou, D. M. Livingston, A. Rao, and K. Rajewsky. 2005. Aberrant T cell differentiation in the absence of Dicer. *J. Exp. Med.* 202: 261–269.
- Chong, M. M., J. P. Rasmussen, A. Y. Rudensky, and D. R. Littman. 2008. The RNaseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. *J. Exp. Med.* 205: 2005–2017.
- Liston, A., L. F. Lu, D. O'Carroll, A. Tarakhovsky, and A. Y. Rudensky. 2008. Dicer-dependent microRNA pathway safeguards regulatory T cell function. *J. Exp. Med.* 205: 1993–2004.
- Zhou, X., L. T. Jeker, B. T. Fife, S. Zhu, M. S. Anderson, M. T. McManus, and J. A. Bluestone. 2008. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. *J. Exp. Med.* 205: 1983–1991.
- Zheng, Y., S. Z. Josefowicz, A. Kas, T. T. Chu, M. A. Gavin, and A. Y. Rudensky. 2007. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. *Nature* 445: 936–940.
- Thai, T. H., D. P. Calado, S. Casola, K. M. Ansel, C. Xiao, Y. Xue, A. Murphy, D. Friendewey, D. Valenzuela, J. L. Kutok, et al. 2007. Regulation of the germinal center response by microRNA-155. *Science* 316: 604–608.
- Rodriguez, A., E. Vigorito, S. Clare, M. V. Warren, P. Couttet, D. R. Soond, S. van Dongen, R. J. Grocock, P. P. Das, E. A. Miska, et al. 2007. Requirement of bic/microRNA-155 for normal immune function. *Science* 316: 608–611.
- Shinkai, Y., G. Rathbun, K. P. Lam, E. M. Oltz, V. Stewart, M. Mendelsohn, J. Charon, M. Datta, F. Young, A. M. Stall, et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. *Cell* 68: 855–867.
- Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. *J. Exp. Med.* 190: 995–1004.
- Pedersen, A. E., M. Gad, N. N. Kristensen, C. Haase, C. H. Nielsen, and M. H. Claesson. 2007. Tolerogenic dendritic cells pulsed with enterobacterial extract suppress development of colitis in the severe combined immunodeficiency transfer model. *Immunology* 121: 526–532.
- O'Connell, R. M., K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc. Natl. Acad. Sci. USA* 104: 1604–1609.
- Suffia, I., S. K. Reckling, G. Salay, and Y. Belkaid. 2005. A role for CD103 in the retention of CD4<sup>+</sup>CD25<sup>+</sup> Treg and control of *Leishmania major* infection. *J. Immunol.* 174: 5444–5455.